Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55390-0114-05 55390-0114 Paclitaxel Paclitaxel Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 23, 2001 July 31, 2013 No Longer Used
00069-1031-30 00069-1031 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00069-1235-30 00069-1235 Talazoparib Talzenna 0.35 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00143-9292-01 00143-9292 Thiotepa Thiotepa 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical Sept. 29, 2023 In Use
00173-0909-13 00173-0909 Niraparib ZEJULA 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0912-13 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0912-61 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0915-13 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0915-61 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00480-4053-56 00480-4053 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 21, 2023 In Use
00480-9772-01 00480-9772 Fludarabine Phosphate Fludarabine Phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 31, 2023 In Use
14789-0013-10 14789-0013 Busulfan Busulfan 60.0 mg/10mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Sept. 15, 2023 In Use
16571-0816-02 16571-0816 Temozolomide TEMOZOLOMIDE 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0816-51 16571-0816 Temozolomide TEMOZOLOMIDE 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0816-41 16571-0816 Temozolomide TEMOZOLOMIDE 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
25021-0253-50 25021-0253 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 1, 2023 In Use
25021-0253-51 25021-0253 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 1, 2023 In Use
25021-0254-08 25021-0254 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 1, 2023 In Use
25021-0254-16 25021-0254 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 1, 2023 In Use
23155-0869-41 23155-0869 Arsenic Trioxide Arsenic Trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Oct. 7, 2021 In Use
23155-0870-41 23155-0870 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous April 22, 2022 In Use
23155-0882-31 23155-0882 Paclitaxel PACLITAXEL 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 31, 2023 In Use
23155-0883-31 23155-0883 Paclitaxel PACLITAXEL 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 31, 2023 In Use
23155-0884-31 23155-0884 Paclitaxel PACLITAXEL 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 31, 2023 In Use
25021-0223-20 25021-0223 Cytarabine Cytarabine 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 1, 2023 In Use
25021-0229-05 25021-0229 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 1, 2023 In Use
25021-0250-20 25021-0250 Mitomycin Mitomycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
25021-0251-50 25021-0251 Mitomycin Mitomycin 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
25021-0252-51 25021-0252 Mitomycin Mitomycin 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
42291-0901-28 42291-0901 Sunitinib Malate Sunitinib Malate 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Oct. 11, 2023 In Use
42291-0902-28 42291-0902 Sunitinib Malate Sunitinib Malate 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Oct. 11, 2023 In Use
42291-0904-28 42291-0904 Sunitinib Malate Sunitinib Malate 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Oct. 11, 2023 In Use
43598-0660-11 43598-0660 Cyclophosphamide Cyclophosphamide 500.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 24, 2023 In Use
43598-0661-11 43598-0661 Cyclophosphamide Cyclophosphamide 1.0 g/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 24, 2023 In Use
43598-0662-11 43598-0662 Cyclophosphamide Cyclophosphamide 2.0 g/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 24, 2023 In Use
50419-0489-01 50419-0489 Sorafenib Nexavar 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, KIT, RET, RET/PTC, FLT3, CRAF, BRAF Oral Oct. 2, 2023 In Use
55150-0392-01 55150-0392 BENDAMUSTINE HYDROCHLORIDE BENDAMUSTINE HYDROCHLORIDE 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 5, 2023 In Use
51991-0821-28 51991-0821 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0821-33 51991-0821 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
51991-0822-28 51991-0822 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0822-33 51991-0822 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
51991-0823-28 51991-0823 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0823-33 51991-0823 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
51991-0824-28 51991-0824 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
51991-0824-33 51991-0824 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
54288-0164-01 54288-0164 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0165-01 54288-0165 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0166-01 54288-0166 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0167-01 54288-0167 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
55150-0391-01 55150-0391 BENDAMUSTINE HYDROCHLORIDE BENDAMUSTINE HYDROCHLORIDE 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 5, 2023 In Use

Found 10,000 results in 6 millisecondsExport these results